Filing Flows › Evofem Biosciences (EVFM) › Q2 2026
Evofem Biosciences (EVFM) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 14, 2026
Evofem Biosciences (EVFM) reported revenue of $2.6M for the second quarter 2026 (Q2 2026), -45% from a year earlier and +193% from the quarter before. Operating margin was -94.5%, net loss $11.0M (419.1% of revenue).
Evofem Biosciences, Q2 2026: revenue $2.6M (-45% year over year), operating margin -94.5%, net loss $11.0M, operating cash flow −$3.1M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $2.6M | +193% | -45% |
| Operating profit | −$2.5M | — | — |
| Net earnings | −$11.0M | — | — |
| Operating cash flow | −$3.1M | -236% | — |
What changed
Revenue was $2.6M in Q2 2026, down 45% year over year and up 193% from the previous quarter.
Operating costs exceeded revenue by $2.5M, an operating margin of -94.5%. Total costs fell 16% while revenue fell 45%. The quarter ended with a net loss of $11.0M, wider than the previous quarter's $5.5M loss. Net interest and other expense of $8.5M was the main reason.
Operating cash flow was −$3.1M. Non-cash charges added back $18K of depreciation and amortization. Working capital and other items added $7.9M.
Questions
What was Evofem Biosciences' revenue in the second quarter 2026?
Evofem Biosciences (EVFM) reported revenue of $2.6M for the second quarter 2026 (Q2 2026), -45% from a year earlier and +193% from the quarter before.
Was Evofem Biosciences profitable in the second quarter 2026?
Operating loss was $2.5M (-94.5% of revenue) and net loss $11.0M.
Source: Evofem Biosciences 10-Q on SEC EDGAR.